Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes

OBJECTIVE: Remogliflozin etabonate (RE), an inhibitor of the sodium-glucose transporter 2, improves glucose profiles in type 2 diabetes. This study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of RE in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: Ten subjects...

Descripción completa

Detalles Bibliográficos
Autores principales: Mudaliar, Sunder, Armstrong, Debra A., Mavian, Annie A., O’Connor-Semmes, Robin, Mydlow, Patricia K., Ye, June, Hussey, Elizabeth K., Nunez, Derek J., Henry, Robert R., Dobbins, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476920/
https://www.ncbi.nlm.nih.gov/pubmed/23011728
http://dx.doi.org/10.2337/dc12-0508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476920/
https://www.ncbi.nlm.nih.gov/pubmed/23011728
http://dx.doi.org/10.2337/dc12-0508

Ejemplares similares